Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor with Paclitaxel and Carboplatin in Advanced Ovarian or Endometrial Cancers
NCT02269293Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2014
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of selinexor in ovarian cancer and endometrial cancer (EC) (4 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Oct 2014; status: completed.
02
Drugs
selinexor
03
Conditions
ovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT02269293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02269293.